Русский
Prospects for using the QRISK3 risk scale in patients with chronic kidney disease and sarcopenia
DOI: https://dx.doi.org/10.18565/nephrology.2024.4.17-22
Sokolova A.V., Stafeeva E.A., Stafeev A.N., Dragunov D.O., Arutyunov G.P.
1) Pirogov Russian National Research Medical University, Moscow, Russia; 2) Sechenov First Moscow State Medical University (Sechenov University), Moscow, Russia; 3) Research Institute for Healthcare Organization and Medical Management, Moscow, Russia
Material and methods. The study involved 143 patients with CKD, including 40 with sarcopenia and 104 without sarcopenia. All patients had their skeletal muscle mass index calculated, muscle strength assessed, their SPPB score calculated and their risk assessed according to the QRISK3 scale. For statistical analysis of the data obtained, the R language, RStudio software, with the following packages were used: tidyverse, gt, modelsummary, ggplot2. At a significance level (p) of less than 0.05, the null hypothesis (H0) was rejected, and changes between the groups were considered reliable.
Results. Patients with sarcopenia had a higher probability of developing cardiovascular diseases, according to the QRISK3 scale. Patients with sarcopenia had higher strength index, strength and skeletal muscle mass index, and lower body mass index compared to patients without sarcopenia. Glomerular filtration rate (SFR) and physical fitness, expressed as points on the SPPB scale, were found to have a significant effect on QRISK3. In patients with sarcopenia, a stronger relationship between age and QRISK3 was observed. An increase in SFR by 1 ml/min/1,73 m² was associated with a decrease in QRISK3 by 0,49%, and the presence of sarcopenia and male gender strengthened this relationship.
Conclusion. The obtained results indicate that kidney function and sarcopenia can significantly affect the assessment of cardiovascular risk according to the QRISK3 scale.
About the Autors
Anna V. Sokolova – PhD in Medicine, Associate Professor, Associate Professor at the Department of Propaedeutics of Internal Diseases No. 1, Institute of Clinical Medicine, Pirogov Russian National Research Medical University (Pirogov University). Address: 1 Ostrovityanova St., Moscow, 117513; e-mail: sokolova2211@gmail.com.
Elena A. Stafeeva – PhD in Medicine, Teaching Assistant at the Department of Propaedeutics of Internal Medicine No. 1, Institute of Clinical Medicine, Pirogov Russian National Research Medical University (Pirogov University). Address: 1 Ostrovityanova St., Moscow, 117513; e-mail: alena.stafeeva16@yandex.ru.
Aleksandr N. Stafeev – Teaching Assistant at the Department of Hospital Therapy No. 2, Sechenov First Moscow State Medical University (Sechenov University). Address: Bldg. 2, 8 Trubetskaya St., Moscow, 119048; e-mail: i@stafeev-pro.ru.
Dmitry O. Dragunov – PhD in Medicine, Associate Professor, Associate Professor at the Department of Propaedeutics of Internal Diseases No. 1, Institute of Clinical Medicine, Pirogov Russian National Research Medical University (Pirogov University). Address: 1 Ostrovityanova St., Moscow, 117513; e-mail: tamops2211@gmail.com.
Grigory P. Arutyunov – Dr.Sci. (Med.), Professor, Corresponding Member of the Russian Academy of Sciences, Director of the Institute of Clinical Medicine, Head of the Department of Propaedeutics of Internal Diseases No. 1, Institute of Clinical Medicine, Pirogov Russian National Research Medical University (Pirogov University).
Address: 1 Ostrovityanova St., Moscow, 117513; e-mail: arutyunov_gp@rsmu.ru.
Similar Articles
